18F-Fluorodeoxyglucose PET/CT-Guided Palliative Radiotherapy Provides Durable Responses to Over a Dozen Sites of Disease in Relapsed Myeloid Sarcoma

Clin Nucl Med. 2020 Nov;45(11):886-887. doi: 10.1097/RLU.0000000000003238.

Abstract

Myeloid sarcoma (MS) is a rare entity, and FDG PET/CT is a useful tool for staging at diagnosis and response assessment. We present a case of a 72-year-old woman diagnosed with multifocal extramedullary MS, using FDG PET/CT to guide palliative radiotherapy to 13 sites of disease over 2 separate relapses with complete and durable local responses and minimal toxicity. This case represents the largest reported burden of disease in MS successfully treated with FDG PET/CT-guided radiotherapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Neoplasm Staging
  • Palliative Care*
  • Positron Emission Tomography Computed Tomography*
  • Radiotherapy, Image-Guided*
  • Recurrence
  • Sarcoma, Myeloid / diagnostic imaging*
  • Sarcoma, Myeloid / pathology
  • Sarcoma, Myeloid / radiotherapy*
  • Treatment Outcome

Substances

  • Fluorodeoxyglucose F18